Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.34 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2571819 | 0.87 | ESR1 (0.48) | ESR1ESR2TTRALOX12ALOX15B | |
| SCHEMBL2569699 | 0.83 | ESR1 (0.41) | ESR1ESR2TTRALOX12ALOX15 | |
| SCHEMBL2571217 | 0.80 | ESR1 (0.46) | ESR1ESR2TTRALOX12ALOX15B | |
| SCHEMBL2570060 | 0.77 | ALOX15 (0.44) | ESR1ESR2TTRALOX12ALOX15 | |
| SCHEMBL7589438 | 0.73 | PTPN1 (0.37) | ESR1ESR2ALOX12ALOX15 | |
| SCHEMBL6504236 | 0.71 | ESR1 (0.42) | ESR1ESR2TTRALOX12ALDH1A1 | |
| SCHEMBL10077113 | 0.69 | ESR1 (0.35) | ESR1ESR2TTRALOX12ALOX15B | |
| SCHEMBL10042940 | 0.69 | MEN1 (0.41) | ALOX12ALOX15MAOB | |
| SCHEMBL13673348 | 0.69 | CYP19A1 (0.38) | ESR1ESR2TTRALOX12ALOX15B | |
| SCHEMBL5856395 | 0.68 | PTPN1 (0.37) | ESR1ESR2TTRALOX12ALOX15B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794141-B1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS INC (US) | 2011-11-09 | — | — | EP | claimed |
| US-20160287555-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2016-10-06 | — | — | US | disclosed |
| US-20160287555-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2016-10-06 | — | — | US | disclosed |
| US-9381186-B2 | Substituted chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9381186-B2 | Substituted chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150352074-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2015-12-10 | — | — | US | disclosed |
| US-20150352074-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2015-12-10 | — | — | US | disclosed |
| US-9138478-B2 | Substituted chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9138478-B2 | Substituted chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2407462-B1 | Substituted chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20140170243-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MEI PHARMA, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140170243-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MEI PHARMA, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20120114766-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120114766-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8084628-B2 | Substituted chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084628-B2 | Substituted chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20090317490-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-12-24 | — | — | US | disclosed |
| US-20090317490-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-12-24 | — | — | US | disclosed |
| US-7601855-B2 | anticancer agents; chemotherapeutic selective agents | NOVOGEN RESEARCH PTY LTD (AU) | 2009-10-13 | — | — | US | disclosed |
| US-7601855-B2 | anticancer agents; chemotherapeutic selective agents | NOVOGEN RESEARCH PTY LTD (AU) | 2009-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352074-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ESR1 1328/4885ESR2 1134/4885TTR 3212/4885 |
| US-20140170243-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ESR1 1328/4885ESR2 1134/4885TTR 3212/4885 |
| US-20120114766-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ESR1 1328/4885ESR2 1134/4885TTR 3212/4885 |
| US-20090317490-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ESR1 1328/4885ESR2 1134/4885TTR 3212/4885 |
| US-20160287555-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ESR1 1328/4885ESR2 1134/4885TTR 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.